ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AQST vs DMAC // FREE CASH FLOW YIELD

Aquestive Therapeutics Inc. (NASDAQ) VS. DiaMedica Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AQST 1 — DMAC 3
▲ FREE CASH FLOW YIELD LEADER: DMAC
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AQST VS. DMAC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AQST DMAC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 58.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -10.45% -5.67% -4.78 DMAC /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -22.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 AQST /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.5 63.0 -25.53 DMAC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $507.1M $513.4M -$6.3M DMAC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AQST REV DMAC REV AQST GROSS % DMAC GROSS % AQST FCF DMAC FCF
FY 2025 $44.5M $0 58.3% — -$53.0M -$29.1M
FY 2024 $57.6M $0 69.0% — -$35.9M -$22.1M
FY 2023 $50.6M $0 — — -$6.4M -$18.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AQST // BETA —
DMAC // BETA —